Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Insmed (INSM) Misses Q4 EPS by 10c, Revenues Beat; Offers FY19 Revenue Outlook Above Consensus
February 22, 2019 7:32 AM ESTInsmed (NASDAQ: INSM) reported Q4 EPS of ($1.16), $0.10 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $6.89 million.
"2018 was a pivotal year for Insmed, with the U.S. approval and launch of ARIKAYCE® (amikacin liposome inhalation suspension), the first and only FDA-approved treatment for patients with refractory Mycobacterium avium complex (MAC) lung disease. We are very pleased with the strong momentum we've seen since launch, including a wide breadth of prescribers, steady additions of new patients, and positive reimbursement trends," commented Will Lewis, Chairman... More
